nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—Antinuclear antibody positive—Lovastatin—atherosclerosis	0.0303	0.0346	CcSEcCtD
Methyldopa—Lupus-like syndrome—Lovastatin—atherosclerosis	0.0292	0.0334	CcSEcCtD
Methyldopa—Lupus-like syndrome—Ezetimibe—atherosclerosis	0.0287	0.0327	CcSEcCtD
Methyldopa—Antinuclear antibody positive—Simvastatin—atherosclerosis	0.0284	0.0324	CcSEcCtD
Methyldopa—Lupus-like syndrome—Simvastatin—atherosclerosis	0.0273	0.0312	CcSEcCtD
Methyldopa—Antinuclear antibody positive—Pravastatin—atherosclerosis	0.0256	0.0293	CcSEcCtD
Methyldopa—Distention—Pravastatin—atherosclerosis	0.0247	0.0282	CcSEcCtD
Methyldopa—VIIth nerve paralysis—Lovastatin—atherosclerosis	0.0168	0.0192	CcSEcCtD
Methyldopa—VIIth nerve paralysis—Simvastatin—atherosclerosis	0.0157	0.0179	CcSEcCtD
Methyldopa—VIIth nerve paralysis—Pravastatin—atherosclerosis	0.0142	0.0162	CcSEcCtD
Methyldopa—Foetor hepaticus—Ezetimibe—atherosclerosis	0.0119	0.0136	CcSEcCtD
Methyldopa—Foetor hepaticus—Simvastatin—atherosclerosis	0.0113	0.013	CcSEcCtD
Methyldopa—Foetor hepaticus—Pravastatin—atherosclerosis	0.0103	0.0117	CcSEcCtD
Methyldopa—Liver disorder—Ezetimibe—atherosclerosis	0.00991	0.0113	CcSEcCtD
Methyldopa—Liver disorder—Simvastatin—atherosclerosis	0.00945	0.0108	CcSEcCtD
Methyldopa—Liver disorder—Pravastatin—atherosclerosis	0.00854	0.00975	CcSEcCtD
Methyldopa—Tenderness—Lovastatin—atherosclerosis	0.00789	0.00901	CcSEcCtD
Methyldopa—Nightmare—Rosuvastatin—atherosclerosis	0.00784	0.00896	CcSEcCtD
Methyldopa—Endocrine disorder—Simvastatin—atherosclerosis	0.00777	0.00887	CcSEcCtD
Methyldopa—Tenderness—Simvastatin—atherosclerosis	0.00738	0.00843	CcSEcCtD
Methyldopa—Gynaecomastia—Rosuvastatin—atherosclerosis	0.00727	0.0083	CcSEcCtD
Methyldopa—Vasculitis—Lovastatin—atherosclerosis	0.00705	0.00806	CcSEcCtD
Methyldopa—Vasculitis—Ezetimibe—atherosclerosis	0.00692	0.0079	CcSEcCtD
Methyldopa—Hepatocellular injury—Ezetimibe—atherosclerosis	0.00675	0.00771	CcSEcCtD
Methyldopa—Tenderness—Pravastatin—atherosclerosis	0.00667	0.00762	CcSEcCtD
Methyldopa—Vasculitis—Simvastatin—atherosclerosis	0.0066	0.00753	CcSEcCtD
Methyldopa—Hepatocellular injury—Simvastatin—atherosclerosis	0.00644	0.00735	CcSEcCtD
Methyldopa—Nightmare—Simvastatin—atherosclerosis	0.00622	0.0071	CcSEcCtD
Methyldopa—Aminosalicylic Acid—ALOX5—atherosclerosis	0.00618	0.247	CrCbGaD
Methyldopa—Gynaecomastia—Lovastatin—atherosclerosis	0.00616	0.00703	CcSEcCtD
Methyldopa—Vasculitis—Pravastatin—atherosclerosis	0.00596	0.00681	CcSEcCtD
Methyldopa—Hepatocellular injury—Pravastatin—atherosclerosis	0.00582	0.00665	CcSEcCtD
Methyldopa—Gynaecomastia—Simvastatin—atherosclerosis	0.00576	0.00658	CcSEcCtD
Methyldopa—Nightmare—Pravastatin—atherosclerosis	0.00562	0.00642	CcSEcCtD
Methyldopa—Haemolytic anaemia—Lovastatin—atherosclerosis	0.00553	0.00632	CcSEcCtD
Methyldopa—Breast disorder—Rosuvastatin—atherosclerosis	0.00533	0.00609	CcSEcCtD
Methyldopa—Gynaecomastia—Pravastatin—atherosclerosis	0.00521	0.00595	CcSEcCtD
Methyldopa—Eczema—Simvastatin—atherosclerosis	0.0052	0.00594	CcSEcCtD
Methyldopa—Haemolytic anaemia—Simvastatin—atherosclerosis	0.00518	0.00591	CcSEcCtD
Methyldopa—Pancreatitis—Rosuvastatin—atherosclerosis	0.005	0.00571	CcSEcCtD
Methyldopa—Mesalazine—ALOX5—atherosclerosis	0.00485	0.194	CrCbGaD
Methyldopa—Eczema—Niacin—atherosclerosis	0.00478	0.00545	CcSEcCtD
Methyldopa—Haemolytic anaemia—Pravastatin—atherosclerosis	0.00468	0.00535	CcSEcCtD
Methyldopa—Liver function test abnormal—Ezetimibe—atherosclerosis	0.00452	0.00517	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Lovastatin—atherosclerosis	0.0045	0.00514	CcSEcCtD
Methyldopa—Jaundice—Rosuvastatin—atherosclerosis	0.00443	0.00506	CcSEcCtD
Methyldopa—Breast disorder—Ezetimibe—atherosclerosis	0.00443	0.00506	CcSEcCtD
Methyldopa—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.0043	0.00491	CcSEcCtD
Methyldopa—Eosinophilia—Lovastatin—atherosclerosis	0.00428	0.00488	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Niacin—atherosclerosis	0.00426	0.00486	CcSEcCtD
Methyldopa—Pancreatitis—Lovastatin—atherosclerosis	0.00423	0.00484	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00421	0.00481	CcSEcCtD
Methyldopa—Eosinophilia—Ezetimibe—atherosclerosis	0.00419	0.00479	CcSEcCtD
Methyldopa—Pancreatitis—Ezetimibe—atherosclerosis	0.00415	0.00474	CcSEcCtD
Methyldopa—Hepatitis—Rosuvastatin—atherosclerosis	0.00408	0.00466	CcSEcCtD
Methyldopa—Eosinophilia—Simvastatin—atherosclerosis	0.004	0.00457	CcSEcCtD
Methyldopa—Aminosalicylic Acid—MPO—atherosclerosis	0.00398	0.159	CrCbGaD
Methyldopa—Erectile dysfunction—Lovastatin—atherosclerosis	0.00398	0.00454	CcSEcCtD
Methyldopa—Liver function test abnormal—Niacin—atherosclerosis	0.00396	0.00453	CcSEcCtD
Methyldopa—Pancreatitis—Simvastatin—atherosclerosis	0.00396	0.00452	CcSEcCtD
Methyldopa—Orthostatic hypotension—Niacin—atherosclerosis	0.00392	0.00448	CcSEcCtD
Methyldopa—Erectile dysfunction—Ezetimibe—atherosclerosis	0.0039	0.00446	CcSEcCtD
Methyldopa—Liver function test abnormal—Pravastatin—atherosclerosis	0.0039	0.00446	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.00381	0.00435	CcSEcCtD
Methyldopa—Infestation NOS—Ezetimibe—atherosclerosis	0.00378	0.00431	CcSEcCtD
Methyldopa—Infestation—Ezetimibe—atherosclerosis	0.00378	0.00431	CcSEcCtD
Methyldopa—Abdominal distension—Niacin—atherosclerosis	0.00373	0.00426	CcSEcCtD
Methyldopa—Erectile dysfunction—Simvastatin—atherosclerosis	0.00372	0.00425	CcSEcCtD
Methyldopa—Jaundice—Ezetimibe—atherosclerosis	0.00368	0.0042	CcSEcCtD
Methyldopa—Abdominal distension—Pravastatin—atherosclerosis	0.00368	0.0042	CcSEcCtD
Methyldopa—Eosinophilia—Pravastatin—atherosclerosis	0.00362	0.00413	CcSEcCtD
Methyldopa—Angina pectoris—Niacin—atherosclerosis	0.00361	0.00413	CcSEcCtD
Methyldopa—Pancreatitis—Pravastatin—atherosclerosis	0.00358	0.00409	CcSEcCtD
Methyldopa—Mental disorder—Rosuvastatin—atherosclerosis	0.00357	0.00408	CcSEcCtD
Methyldopa—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00357	0.00408	CcSEcCtD
Methyldopa—Angina pectoris—Pravastatin—atherosclerosis	0.00356	0.00406	CcSEcCtD
Methyldopa—Jaundice—Simvastatin—atherosclerosis	0.00351	0.00401	CcSEcCtD
Methyldopa—Flatulence—Rosuvastatin—atherosclerosis	0.0035	0.004	CcSEcCtD
Methyldopa—Hepatitis—Lovastatin—atherosclerosis	0.00346	0.00395	CcSEcCtD
Methyldopa—Erectile dysfunction—Niacin—atherosclerosis	0.00342	0.0039	CcSEcCtD
Methyldopa—Hepatitis—Ezetimibe—atherosclerosis	0.00339	0.00387	CcSEcCtD
Methyldopa—Erectile dysfunction—Pravastatin—atherosclerosis	0.00336	0.00384	CcSEcCtD
Methyldopa—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00333	0.00381	CcSEcCtD
Methyldopa—Weight increased—Pravastatin—atherosclerosis	0.00332	0.0038	CcSEcCtD
Methyldopa—Hepatitis—Simvastatin—atherosclerosis	0.00323	0.00369	CcSEcCtD
Methyldopa—Jaundice—Niacin—atherosclerosis	0.00322	0.00368	CcSEcCtD
Methyldopa—Jaundice—Pravastatin—atherosclerosis	0.00317	0.00363	CcSEcCtD
Methyldopa—Mesalazine—MPO—atherosclerosis	0.00312	0.125	CrCbGaD
Methyldopa—Angiopathy—Ezetimibe—atherosclerosis	0.00308	0.00351	CcSEcCtD
Methyldopa—Mediastinal disorder—Ezetimibe—atherosclerosis	0.00306	0.00349	CcSEcCtD
Methyldopa—Arthralgia—Rosuvastatin—atherosclerosis	0.00302	0.00345	CcSEcCtD
Methyldopa—Myalgia—Rosuvastatin—atherosclerosis	0.00302	0.00345	CcSEcCtD
Methyldopa—Mental disorder—Ezetimibe—atherosclerosis	0.00297	0.00339	CcSEcCtD
Methyldopa—Hepatitis—Niacin—atherosclerosis	0.00297	0.00339	CcSEcCtD
Methyldopa—Flatulence—Lovastatin—atherosclerosis	0.00297	0.00339	CcSEcCtD
Methyldopa—Hepatitis—Pravastatin—atherosclerosis	0.00292	0.00334	CcSEcCtD
Methyldopa—Flatulence—Ezetimibe—atherosclerosis	0.00291	0.00332	CcSEcCtD
Methyldopa—Infection—Rosuvastatin—atherosclerosis	0.00288	0.00329	CcSEcCtD
Methyldopa—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00284	0.00325	CcSEcCtD
Methyldopa—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00284	0.00324	CcSEcCtD
Methyldopa—Mental disorder—Simvastatin—atherosclerosis	0.00283	0.00324	CcSEcCtD
Methyldopa—Flatulence—Simvastatin—atherosclerosis	0.00277	0.00317	CcSEcCtD
Methyldopa—Mesalazine—PPARG—atherosclerosis	0.00277	0.111	CrCbGaD
Methyldopa—Cardiac disorder—Pravastatin—atherosclerosis	0.00271	0.0031	CcSEcCtD
Methyldopa—Angiopathy—Niacin—atherosclerosis	0.00269	0.00308	CcSEcCtD
Methyldopa—Leukopenia—Lovastatin—atherosclerosis	0.00269	0.00308	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00264	0.00302	CcSEcCtD
Methyldopa—Paraesthesia—Rosuvastatin—atherosclerosis	0.0026	0.00297	CcSEcCtD
Methyldopa—Arthralgia—Lovastatin—atherosclerosis	0.00256	0.00293	CcSEcCtD
Methyldopa—Myalgia—Lovastatin—atherosclerosis	0.00256	0.00293	CcSEcCtD
Methyldopa—Flatulence—Niacin—atherosclerosis	0.00255	0.00291	CcSEcCtD
Methyldopa—Leukopenia—Simvastatin—atherosclerosis	0.00252	0.00288	CcSEcCtD
Methyldopa—Myalgia—Ezetimibe—atherosclerosis	0.00251	0.00287	CcSEcCtD
Methyldopa—Arthralgia—Ezetimibe—atherosclerosis	0.00251	0.00287	CcSEcCtD
Methyldopa—Flatulence—Pravastatin—atherosclerosis	0.00251	0.00286	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.0025	0.00285	CcSEcCtD
Methyldopa—Constipation—Rosuvastatin—atherosclerosis	0.00248	0.00283	CcSEcCtD
Methyldopa—Infection—Lovastatin—atherosclerosis	0.00244	0.00279	CcSEcCtD
Methyldopa—Thrombocytopenia—Lovastatin—atherosclerosis	0.0024	0.00275	CcSEcCtD
Methyldopa—Arthralgia—Simvastatin—atherosclerosis	0.0024	0.00274	CcSEcCtD
Methyldopa—Myalgia—Simvastatin—atherosclerosis	0.0024	0.00274	CcSEcCtD
Methyldopa—Infection—Ezetimibe—atherosclerosis	0.00239	0.00273	CcSEcCtD
Methyldopa—Nervous system disorder—Ezetimibe—atherosclerosis	0.00236	0.0027	CcSEcCtD
Methyldopa—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00236	0.00269	CcSEcCtD
Methyldopa—Skin disorder—Ezetimibe—atherosclerosis	0.00234	0.00267	CcSEcCtD
Methyldopa—Leukopenia—Niacin—atherosclerosis	0.00231	0.00264	CcSEcCtD
Methyldopa—Oedema—Simvastatin—atherosclerosis	0.0023	0.00262	CcSEcCtD
Methyldopa—Infection—Simvastatin—atherosclerosis	0.00228	0.00261	CcSEcCtD
Methyldopa—Leukopenia—Pravastatin—atherosclerosis	0.00228	0.0026	CcSEcCtD
Methyldopa—Thrombocytopenia—Simvastatin—atherosclerosis	0.00225	0.00257	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00224	0.00256	CcSEcCtD
Methyldopa—Paraesthesia—Lovastatin—atherosclerosis	0.00221	0.00252	CcSEcCtD
Methyldopa—Arthralgia—Niacin—atherosclerosis	0.0022	0.00251	CcSEcCtD
Methyldopa—Myalgia—Niacin—atherosclerosis	0.0022	0.00251	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00219	0.00251	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00219	0.0025	CcSEcCtD
Methyldopa—Myalgia—Pravastatin—atherosclerosis	0.00217	0.00247	CcSEcCtD
Methyldopa—Arthralgia—Pravastatin—atherosclerosis	0.00217	0.00247	CcSEcCtD
Methyldopa—Paraesthesia—Ezetimibe—atherosclerosis	0.00216	0.00247	CcSEcCtD
Methyldopa—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00214	0.00244	CcSEcCtD
Methyldopa—Oedema—Niacin—atherosclerosis	0.00211	0.00241	CcSEcCtD
Methyldopa—Constipation—Lovastatin—atherosclerosis	0.0021	0.0024	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00209	0.00239	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00208	0.00238	CcSEcCtD
Methyldopa—Asthenia—Rosuvastatin—atherosclerosis	0.00208	0.00237	CcSEcCtD
Methyldopa—Oedema—Pravastatin—atherosclerosis	0.00208	0.00237	CcSEcCtD
Methyldopa—Infection—Pravastatin—atherosclerosis	0.00206	0.00236	CcSEcCtD
Methyldopa—Paraesthesia—Simvastatin—atherosclerosis	0.00206	0.00236	CcSEcCtD
Methyldopa—Constipation—Ezetimibe—atherosclerosis	0.00206	0.00235	CcSEcCtD
Methyldopa—Skin disorder—Niacin—atherosclerosis	0.00205	0.00234	CcSEcCtD
Methyldopa—Thrombocytopenia—Pravastatin—atherosclerosis	0.00203	0.00232	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00198	0.00227	CcSEcCtD
Methyldopa—Diarrhoea—Rosuvastatin—atherosclerosis	0.00198	0.00226	CcSEcCtD
Methyldopa—Constipation—Simvastatin—atherosclerosis	0.00196	0.00224	CcSEcCtD
Methyldopa—Body temperature increased—Lovastatin—atherosclerosis	0.00194	0.00222	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00192	0.00219	CcSEcCtD
Methyldopa—Dizziness—Rosuvastatin—atherosclerosis	0.00192	0.00219	CcSEcCtD
Methyldopa—Body temperature increased—Ezetimibe—atherosclerosis	0.0019	0.00217	CcSEcCtD
Methyldopa—Paraesthesia—Niacin—atherosclerosis	0.00189	0.00216	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00189	0.00216	CcSEcCtD
Methyldopa—Paraesthesia—Pravastatin—atherosclerosis	0.00186	0.00213	CcSEcCtD
Methyldopa—Rash—Rosuvastatin—atherosclerosis	0.00183	0.00209	CcSEcCtD
Methyldopa—Dermatitis—Rosuvastatin—atherosclerosis	0.00183	0.00208	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Niacin—atherosclerosis	0.00182	0.00208	CcSEcCtD
Methyldopa—Body temperature increased—Simvastatin—atherosclerosis	0.00182	0.00207	CcSEcCtD
Methyldopa—Headache—Rosuvastatin—atherosclerosis	0.00182	0.00207	CcSEcCtD
Methyldopa—Hypersensitivity—Lovastatin—atherosclerosis	0.00181	0.00207	CcSEcCtD
Methyldopa—Constipation—Pravastatin—atherosclerosis	0.00178	0.00203	CcSEcCtD
Methyldopa—Hypersensitivity—Ezetimibe—atherosclerosis	0.00177	0.00203	CcSEcCtD
Methyldopa—Asthenia—Lovastatin—atherosclerosis	0.00176	0.00201	CcSEcCtD
Methyldopa—Asthenia—Ezetimibe—atherosclerosis	0.00173	0.00197	CcSEcCtD
Methyldopa—Nausea—Rosuvastatin—atherosclerosis	0.00172	0.00197	CcSEcCtD
Methyldopa—Hypersensitivity—Simvastatin—atherosclerosis	0.00169	0.00193	CcSEcCtD
Methyldopa—Diarrhoea—Lovastatin—atherosclerosis	0.00168	0.00192	CcSEcCtD
Methyldopa—Body temperature increased—Niacin—atherosclerosis	0.00167	0.0019	CcSEcCtD
Methyldopa—Asthenia—Simvastatin—atherosclerosis	0.00165	0.00188	CcSEcCtD
Methyldopa—Diarrhoea—Ezetimibe—atherosclerosis	0.00165	0.00188	CcSEcCtD
Methyldopa—Body temperature increased—Pravastatin—atherosclerosis	0.00164	0.00188	CcSEcCtD
Methyldopa—Dizziness—Lovastatin—atherosclerosis	0.00162	0.00185	CcSEcCtD
Methyldopa—Dizziness—Ezetimibe—atherosclerosis	0.00159	0.00182	CcSEcCtD
Methyldopa—Diarrhoea—Simvastatin—atherosclerosis	0.00157	0.0018	CcSEcCtD
Methyldopa—Vomiting—Lovastatin—atherosclerosis	0.00156	0.00178	CcSEcCtD
Methyldopa—Hypersensitivity—Niacin—atherosclerosis	0.00155	0.00177	CcSEcCtD
Methyldopa—Rash—Lovastatin—atherosclerosis	0.00155	0.00177	CcSEcCtD
Methyldopa—Dermatitis—Lovastatin—atherosclerosis	0.00155	0.00177	CcSEcCtD
Methyldopa—Headache—Lovastatin—atherosclerosis	0.00154	0.00176	CcSEcCtD
Methyldopa—Vomiting—Ezetimibe—atherosclerosis	0.00153	0.00175	CcSEcCtD
Methyldopa—Hypersensitivity—Pravastatin—atherosclerosis	0.00153	0.00175	CcSEcCtD
Methyldopa—Dizziness—Simvastatin—atherosclerosis	0.00152	0.00173	CcSEcCtD
Methyldopa—Rash—Ezetimibe—atherosclerosis	0.00152	0.00173	CcSEcCtD
Methyldopa—Dermatitis—Ezetimibe—atherosclerosis	0.00152	0.00173	CcSEcCtD
Methyldopa—Asthenia—Niacin—atherosclerosis	0.00151	0.00173	CcSEcCtD
Methyldopa—Headache—Ezetimibe—atherosclerosis	0.00151	0.00172	CcSEcCtD
Methyldopa—Aminosalicylic Acid—PTGS2—atherosclerosis	0.00149	0.0597	CrCbGaD
Methyldopa—Asthenia—Pravastatin—atherosclerosis	0.00149	0.0017	CcSEcCtD
Methyldopa—Vomiting—Simvastatin—atherosclerosis	0.00146	0.00167	CcSEcCtD
Methyldopa—Nausea—Lovastatin—atherosclerosis	0.00146	0.00167	CcSEcCtD
Methyldopa—Rash—Simvastatin—atherosclerosis	0.00145	0.00165	CcSEcCtD
Methyldopa—Dermatitis—Simvastatin—atherosclerosis	0.00145	0.00165	CcSEcCtD
Methyldopa—Diarrhoea—Niacin—atherosclerosis	0.00144	0.00165	CcSEcCtD
Methyldopa—Headache—Simvastatin—atherosclerosis	0.00144	0.00164	CcSEcCtD
Methyldopa—Nausea—Ezetimibe—atherosclerosis	0.00143	0.00163	CcSEcCtD
Methyldopa—Diarrhoea—Pravastatin—atherosclerosis	0.00142	0.00162	CcSEcCtD
Methyldopa—Epinephrine—TNF—atherosclerosis	0.00142	0.0568	CrCbGaD
Methyldopa—Dizziness—Niacin—atherosclerosis	0.00139	0.00159	CcSEcCtD
Methyldopa—Dizziness—Pravastatin—atherosclerosis	0.00137	0.00157	CcSEcCtD
Methyldopa—Nausea—Simvastatin—atherosclerosis	0.00136	0.00156	CcSEcCtD
Methyldopa—Vomiting—Niacin—atherosclerosis	0.00134	0.00153	CcSEcCtD
Methyldopa—Rash—Niacin—atherosclerosis	0.00133	0.00152	CcSEcCtD
Methyldopa—Dermatitis—Niacin—atherosclerosis	0.00133	0.00152	CcSEcCtD
Methyldopa—Headache—Niacin—atherosclerosis	0.00132	0.00151	CcSEcCtD
Methyldopa—Vomiting—Pravastatin—atherosclerosis	0.00132	0.00151	CcSEcCtD
Methyldopa—Rash—Pravastatin—atherosclerosis	0.00131	0.0015	CcSEcCtD
Methyldopa—Dermatitis—Pravastatin—atherosclerosis	0.00131	0.00149	CcSEcCtD
Methyldopa—Headache—Pravastatin—atherosclerosis	0.0013	0.00149	CcSEcCtD
Methyldopa—Nausea—Niacin—atherosclerosis	0.00125	0.00143	CcSEcCtD
Methyldopa—Nausea—Pravastatin—atherosclerosis	0.00123	0.00141	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—atherosclerosis	0.00117	0.0469	CrCbGaD
Methyldopa—ADRA2A—Metabolism—LDLRAP1—atherosclerosis	0.000169	0.0017	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PDGFB—atherosclerosis	0.000168	0.00168	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NAMPT—atherosclerosis	0.000166	0.00167	CbGpPWpGaD
Methyldopa—COMT—Metabolism—LIPC—atherosclerosis	0.000165	0.00166	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOC3—atherosclerosis	0.000164	0.00165	CbGpPWpGaD
Methyldopa—COMT—Metabolism—LDLR—atherosclerosis	0.000163	0.00164	CbGpPWpGaD
Methyldopa—DDC—Metabolism—HMGCR—atherosclerosis	0.000162	0.00163	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VWF—atherosclerosis	0.000161	0.00162	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CETP—atherosclerosis	0.000159	0.0016	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLTP—atherosclerosis	0.000159	0.0016	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—APOA1—atherosclerosis	0.000158	0.00159	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR2—atherosclerosis	0.000158	0.00158	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—EDNRA—atherosclerosis	0.000158	0.00158	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—AGT—atherosclerosis	0.000156	0.00157	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—PPARA—atherosclerosis	0.000154	0.00155	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—F7—atherosclerosis	0.000154	0.00155	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GHRL—atherosclerosis	0.000154	0.00154	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SCARB1—atherosclerosis	0.000152	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—F2—atherosclerosis	0.000151	0.00152	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—atherosclerosis	0.000149	0.0015	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—atherosclerosis	0.000148	0.00149	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—atherosclerosis	0.000145	0.00145	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—APOA1—atherosclerosis	0.000145	0.00145	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCA1—atherosclerosis	0.000144	0.00145	CbGpPWpGaD
Methyldopa—COMT—Metabolism—HMGCR—atherosclerosis	0.000144	0.00145	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG8—atherosclerosis	0.000138	0.00138	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LTA4H—atherosclerosis	0.000138	0.00138	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAT—atherosclerosis	0.000137	0.00138	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—KNG1—atherosclerosis	0.000135	0.00136	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AGTR1—atherosclerosis	0.000134	0.00135	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IGF1—atherosclerosis	0.000132	0.00133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL4—atherosclerosis	0.000131	0.00132	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—UTS2—atherosclerosis	0.000128	0.00129	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCA1—atherosclerosis	0.000128	0.00129	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—atherosclerosis	0.000126	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ALB—atherosclerosis	0.000126	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—atherosclerosis	0.000124	0.00124	CbGpPWpGaD
Methyldopa—DDC—Metabolism—HMOX1—atherosclerosis	0.000124	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CASR—atherosclerosis	0.000123	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KNG1—atherosclerosis	0.000121	0.00121	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAUR—atherosclerosis	0.000119	0.0012	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOB—atherosclerosis	0.000119	0.00119	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLG—atherosclerosis	0.000117	0.00117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—UTS2—atherosclerosis	0.000117	0.00117	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTM1—atherosclerosis	0.000115	0.00116	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ALB—atherosclerosis	0.000115	0.00115	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR2—atherosclerosis	0.000115	0.00115	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—F2—atherosclerosis	0.000114	0.00115	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—EDN1—atherosclerosis	0.000114	0.00114	CbGpPWpGaD
Methyldopa—DDC—Metabolism—LPL—atherosclerosis	0.000113	0.00114	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL5—atherosclerosis	0.000113	0.00113	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SOD1—atherosclerosis	0.000112	0.00113	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CX3CR1—atherosclerosis	0.000112	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CASR—atherosclerosis	0.000112	0.00112	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GPX1—atherosclerosis	0.00011	0.00111	CbGpPWpGaD
Methyldopa—COMT—Metabolism—HMOX1—atherosclerosis	0.00011	0.00111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CX3CL1—atherosclerosis	0.00011	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG1—atherosclerosis	0.000109	0.00109	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CD36—atherosclerosis	0.000108	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRH1—atherosclerosis	0.000107	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF2—atherosclerosis	0.000106	0.00107	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOB—atherosclerosis	0.000105	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR2—atherosclerosis	0.000104	0.00105	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOB—atherosclerosis	0.000103	0.00104	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTM1—atherosclerosis	0.000102	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LCAT—atherosclerosis	0.000102	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FABP4—atherosclerosis	0.000102	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—atherosclerosis	0.000102	0.00103	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MTHFR—atherosclerosis	0.000102	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—atherosclerosis	0.000101	0.00102	CbGpPWpGaD
Methyldopa—COMT—Metabolism—LPL—atherosclerosis	0.000101	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA4—atherosclerosis	0.0001	0.00101	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARA—atherosclerosis	0.0001	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP7A1—atherosclerosis	9.86e-05	0.000991	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPX1—atherosclerosis	9.81e-05	0.000986	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AGT—atherosclerosis	9.69e-05	0.000974	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PRKCG—atherosclerosis	9.58e-05	0.000963	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CD36—atherosclerosis	9.55e-05	0.000961	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOE—atherosclerosis	9.49e-05	0.000954	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AGT—atherosclerosis	9.43e-05	0.000948	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CAV1—atherosclerosis	9.4e-05	0.000946	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOA1—atherosclerosis	9.38e-05	0.000943	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CD36—atherosclerosis	9.36e-05	0.000942	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP27A1—atherosclerosis	9.11e-05	0.000916	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MTHFR—atherosclerosis	9.05e-05	0.00091	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL3—atherosclerosis	8.94e-05	0.000899	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR2—atherosclerosis	8.91e-05	0.000895	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDNRA—atherosclerosis	8.91e-05	0.000895	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARA—atherosclerosis	8.88e-05	0.000893	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—F2—atherosclerosis	8.71e-05	0.000876	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GHRL—atherosclerosis	8.68e-05	0.000873	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—atherosclerosis	8.65e-05	0.00087	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA2—atherosclerosis	8.64e-05	0.000869	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALOX5AP—atherosclerosis	8.64e-05	0.000869	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALOX15—atherosclerosis	8.64e-05	0.000869	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLA2G2A—atherosclerosis	8.64e-05	0.000869	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PDGFB—atherosclerosis	8.64e-05	0.000868	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AGT—atherosclerosis	8.6e-05	0.000865	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—atherosclerosis	8.57e-05	0.000861	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MMP1—atherosclerosis	8.54e-05	0.000858	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG5—atherosclerosis	8.53e-05	0.000858	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—atherosclerosis	8.43e-05	0.000847	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA4—atherosclerosis	8.39e-05	0.000844	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAV1—atherosclerosis	8.35e-05	0.00084	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOA1—atherosclerosis	8.33e-05	0.000838	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—atherosclerosis	8.27e-05	0.000831	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPA—atherosclerosis	8.24e-05	0.000829	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CAV1—atherosclerosis	8.18e-05	0.000823	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—atherosclerosis	8.18e-05	0.000823	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—APOA1—atherosclerosis	8.17e-05	0.000821	CbGpPWpGaD
Methyldopa—DDC—Metabolism—INS—atherosclerosis	8.11e-05	0.000815	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDNRA—atherosclerosis	8.09e-05	0.000813	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR2—atherosclerosis	8.09e-05	0.000813	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—atherosclerosis	8.06e-05	0.000811	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BGN—atherosclerosis	7.98e-05	0.000803	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—atherosclerosis	7.94e-05	0.000798	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA5—atherosclerosis	7.9e-05	0.000795	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GHRL—atherosclerosis	7.88e-05	0.000792	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—F2—atherosclerosis	7.79e-05	0.000783	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—atherosclerosis	7.76e-05	0.000781	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL4—atherosclerosis	7.73e-05	0.000777	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—atherosclerosis	7.7e-05	0.000774	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—KNG1—atherosclerosis	7.62e-05	0.000766	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLA2G1B—atherosclerosis	7.61e-05	0.000765	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—atherosclerosis	7.61e-05	0.000765	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGTR1—atherosclerosis	7.57e-05	0.000761	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—atherosclerosis	7.46e-05	0.00075	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—atherosclerosis	7.43e-05	0.000747	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALOX5—atherosclerosis	7.35e-05	0.000739	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—atherosclerosis	7.34e-05	0.000738	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA2—atherosclerosis	7.22e-05	0.000726	CbGpPWpGaD
Methyldopa—COMT—Metabolism—INS—atherosclerosis	7.2e-05	0.000724	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—atherosclerosis	7.11e-05	0.000715	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KNG1—atherosclerosis	6.92e-05	0.000695	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—UTS2—atherosclerosis	6.89e-05	0.000693	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGTR1—atherosclerosis	6.88e-05	0.000691	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—atherosclerosis	6.83e-05	0.000686	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CR1—atherosclerosis	6.61e-05	0.000664	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASR—atherosclerosis	6.61e-05	0.000664	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—atherosclerosis	6.6e-05	0.000664	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NAMPT—atherosclerosis	6.59e-05	0.000663	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LIPC—atherosclerosis	6.55e-05	0.000658	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOC3—atherosclerosis	6.51e-05	0.000654	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—atherosclerosis	6.5e-05	0.000654	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—atherosclerosis	6.48e-05	0.000652	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CL1—atherosclerosis	6.48e-05	0.000652	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—atherosclerosis	6.47e-05	0.000651	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LDLR—atherosclerosis	6.47e-05	0.00065	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDN1—atherosclerosis	6.42e-05	0.000645	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCL5—atherosclerosis	6.37e-05	0.00064	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CETP—atherosclerosis	6.32e-05	0.000635	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—atherosclerosis	6.31e-05	0.000635	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—atherosclerosis	6.19e-05	0.000622	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR2—atherosclerosis	6.14e-05	0.000618	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—atherosclerosis	6.14e-05	0.000617	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MMP3—atherosclerosis	6.13e-05	0.000616	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCG—atherosclerosis	6.06e-05	0.000609	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SCARB1—atherosclerosis	6.05e-05	0.000608	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDN1—atherosclerosis	5.83e-05	0.000586	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL5—atherosclerosis	5.78e-05	0.000582	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—atherosclerosis	5.77e-05	0.000581	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMGCR—atherosclerosis	5.71e-05	0.000574	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—atherosclerosis	5.52e-05	0.000555	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCG—atherosclerosis	5.5e-05	0.000553	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VWF—atherosclerosis	5.48e-05	0.00055	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOC3—atherosclerosis	5.44e-05	0.000547	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LDLR—atherosclerosis	5.41e-05	0.000544	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGT—atherosclerosis	5.33e-05	0.000536	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL3—atherosclerosis	5.28e-05	0.000531	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCA1—atherosclerosis	5.09e-05	0.000512	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCF1—atherosclerosis	5.06e-05	0.000509	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—F2—atherosclerosis	4.92e-05	0.000495	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGT—atherosclerosis	4.84e-05	0.000486	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR2—atherosclerosis	4.78e-05	0.00048	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRA—atherosclerosis	4.78e-05	0.00048	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CYBA—atherosclerosis	4.76e-05	0.000478	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—atherosclerosis	4.71e-05	0.000474	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GHRL—atherosclerosis	4.66e-05	0.000468	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PARP1—atherosclerosis	4.66e-05	0.000468	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLAT—atherosclerosis	4.66e-05	0.000468	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—F2—atherosclerosis	4.47e-05	0.00045	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—atherosclerosis	4.46e-05	0.000448	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—atherosclerosis	4.37e-05	0.000439	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—atherosclerosis	4.28e-05	0.00043	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—atherosclerosis	4.22e-05	0.000424	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOB—atherosclerosis	4.18e-05	0.000421	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—atherosclerosis	4.09e-05	0.000411	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KNG1—atherosclerosis	4.09e-05	0.000411	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—atherosclerosis	4.07e-05	0.000409	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR1—atherosclerosis	4.06e-05	0.000408	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPL—atherosclerosis	4e-05	0.000402	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—atherosclerosis	3.98e-05	0.000401	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLG—atherosclerosis	3.96e-05	0.000398	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—atherosclerosis	3.9e-05	0.000392	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD36—atherosclerosis	3.8e-05	0.000382	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	3.75e-05	0.000377	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	3.62e-05	0.000364	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	3.6e-05	0.000362	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—atherosclerosis	3.6e-05	0.000362	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARA—atherosclerosis	3.53e-05	0.000355	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOB—atherosclerosis	3.5e-05	0.000352	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	3.47e-05	0.000349	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	3.44e-05	0.000346	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AGT—atherosclerosis	3.42e-05	0.000344	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	3.42e-05	0.000344	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—atherosclerosis	3.35e-05	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPL—atherosclerosis	3.34e-05	0.000336	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAV1—atherosclerosis	3.32e-05	0.000334	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA1—atherosclerosis	3.31e-05	0.000333	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—atherosclerosis	3.27e-05	0.000329	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	3.25e-05	0.000327	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	3.16e-05	0.000318	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	3.15e-05	0.000317	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—atherosclerosis	3.02e-05	0.000304	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	2.93e-05	0.000294	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—atherosclerosis	2.92e-05	0.000293	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—atherosclerosis	2.9e-05	0.000292	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—INS—atherosclerosis	2.86e-05	0.000288	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGT—atherosclerosis	2.86e-05	0.000287	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—atherosclerosis	2.84e-05	0.000286	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—atherosclerosis	2.8e-05	0.000282	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—atherosclerosis	2.8e-05	0.000282	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	2.77e-05	0.000279	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	2.77e-05	0.000278	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	2.67e-05	0.000269	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2—atherosclerosis	2.64e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—atherosclerosis	2.62e-05	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	2.53e-05	0.000254	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—atherosclerosis	2.51e-05	0.000252	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	2.42e-05	0.000243	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—INS—atherosclerosis	2.39e-05	0.000241	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	2.35e-05	0.000237	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	2.31e-05	0.000233	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—atherosclerosis	2.29e-05	0.000231	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	2.2e-05	0.000221	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	2.1e-05	0.000211	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.86e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.8e-05	0.000181	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.77e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	1.68e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	1.67e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	1.64e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	1.63e-05	0.000164	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	1.51e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.5e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.43e-05	0.000144	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.39e-05	0.000139	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—atherosclerosis	1.15e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.05e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	9.64e-06	9.7e-05	CbGpPWpGaD
